The review highlights that despite understanding the role of smooth muscle cell proliferation in restenosis post-PTCA, systemic pharmacological interventions have failed to prevent it, suggesting a need for new delivery methods or deeper mechanistic understanding.
Answers are grounded in this paper and cite their sources.
Systemic antiproliferative agents have not reduced restenosis; challenges this strategy and leaves open targeted delivery or alternative mechanisms.
Restenosis after successful percutaneous transluminal coronary angioplasty (PTCA) remains an unsolved medical problem. The search for the underlying pathophysiological mechanisms have identified intimal proliferation of smooth muscle cells (SMC) to be the prevailing cause of late restenosis, with endothelial cells (EC) and platelets being important participators in the process. According to the most accepted present theory, SMC would be stimulated to migrate and proliferate shortly after the angioplasty by the release of growth factors from injured EC and accumulated platelets. However, clinical trials of agents interfering with these mechanisms have not significantly diminished the rate of restenosis, which suggest both that our knowledge of the process is incomplete, and that new ways of administering the agents may be required.
No takes yet. Share an insight, caveat, or question.
Lövqvist et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: